ProShare Advisors
OVID icon

ProShare Advisors’s Ovid Therapeutics OVID Stock Holding History

ProShare Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,754
Closed -$3.98K – 2156
2025
Q1 		$3.98K Sell
12,754
-3,830
-23% -$2.35K ﹤0.01% 2078
2024
Q4 		$15.5K Buy
16,584
+1,263
+8% +$1.41K ﹤0.01% 2258
2024
Q3 		$18.1K Buy
15,321
+2,956
+24% +$3.09K ﹤0.01% 2049
2024
Q2 		$9.51K Sell
12,365
-3,301
-21% -$9.19K ﹤0.01% 1838
2024
Q1 		$47.8K Buy
15,666
+1,281
+9% +$4.29K ﹤0.01% 1908
2023
Q4 		$46.3K Buy
+14,385
New +$49.2K ﹤0.01% 1870
2021
Q4 		– Sell
-14,511
Closed -$49K – 2345
2021
Q3 		$49K Buy
14,511
+2,328
+19% +$8.49K ﹤0.01% 1966
2021
Q2 		$48K Sell
12,183
-9,306
-43% -$36.7K ﹤0.01% 2361
2021
Q1 		$86K Buy
21,489
+1,156
+6% +$3.84K ﹤0.01% 2182
2020
Q4 		$47K Buy
+20,333
New +$94.8K ﹤0.01% 2050

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

ProShare Advisors's OVID Position: Q2 2025 in Review

ProShare Advisors sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 12,754 shares — an estimated $3.98K sold.

ProShare Advisors first reported a position in OVID in Q4 2020 and held it in 10 quarters. The position peaked at $86K in Q1 2021. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • ProShare Advisors reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 12,754 Ovid Therapeutics shares in Q2 2025, an estimated $3.98K.
  • ProShare Advisors first reported a position in Ovid Therapeutics in Q4 2020 and held it in 10 quarters.
  • ProShare Advisors's Ovid Therapeutics position peaked at $86K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.